280 related articles for article (PubMed ID: 23041907)
1. Emerging therapeutic agents to lower lipoprotein (a) levels.
Kolski B; Tsimikas S
Curr Opin Lipidol; 2012 Dec; 23(6):560-8. PubMed ID: 23041907
[TBL] [Abstract][Full Text] [Related]
2. When should we measure lipoprotein (a)?
Kostner KM; März W; Kostner GM
Eur Heart J; 2013 Nov; 34(42):3268-76. PubMed ID: 23735860
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein (a): gene genie.
Durrington PN; Schofield JD; Siahmansur T; Soran H
Curr Opin Lipidol; 2014 Aug; 25(4):289-96. PubMed ID: 24977982
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
Tsimikas S
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471
[TBL] [Abstract][Full Text] [Related]
6. Latest developments in the treatment of lipoprotein (a).
Bos S; Yayha R; van Lennep JE
Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
Tsimikas S; Hall JL
J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) as a therapeutic target in cardiovascular disease.
Koschinsky M; Boffa M
Expert Opin Ther Targets; 2014 Jul; 18(7):747-57. PubMed ID: 24848373
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a): new insights from modern genomics.
Afshar M; Thanassoulis G
Curr Opin Lipidol; 2017 Apr; 28(2):170-176. PubMed ID: 28059953
[TBL] [Abstract][Full Text] [Related]
10. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
Fras Z
Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) and Cardiovascular Diseases - Revisited.
Jang AY; Han SH; Sohn IS; Oh PC; Koh KK
Circ J; 2020 May; 84(6):867-874. PubMed ID: 32336721
[TBL] [Abstract][Full Text] [Related]
12. The Role of Antisense Therapies Targeting Lipoprotein(a).
Plakogiannis R; Sorbera M; Fischetti B; Chen M
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
[TBL] [Abstract][Full Text] [Related]
13. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
Hung MY; Tsimikas S
Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
[TBL] [Abstract][Full Text] [Related]
15. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.
Stulnig TM; Morozzi C; Reindl-Schwaighofer R; Stefanutti C
Curr Atheroscler Rep; 2019 Jul; 21(10):37. PubMed ID: 31350625
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in modulating atherogenic lipoproteins.
White CR; Goldberg DI; Anantharamaiah GM
Curr Opin Lipidol; 2015 Oct; 26(5):369-75. PubMed ID: 26270809
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
Tada H; Takamura M; Kawashiri MA
J Atheroscler Thromb; 2019 Jul; 26(7):583-591. PubMed ID: 31061262
[TBL] [Abstract][Full Text] [Related]
18. Relationship of apoE polymorphism with lipoprotein(a), apoA, apoB and lipid levels in atherosclerotic infarct.
Tascilar N; Dursun A; Ankarali H; Mungan G; Sumbuloglu V; Ekem S; Bozdogan S; Baris S; Aciman E; Cabuk F
J Neurol Sci; 2009 Feb; 277(1-2):17-21. PubMed ID: 18945448
[TBL] [Abstract][Full Text] [Related]
19. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
[TBL] [Abstract][Full Text] [Related]
20. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
Rached FH; Chapman MJ; Kontush A
Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
